Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First-in-Human trial begins for hepatitis c vaccine

NCT ID NCT07237282

Summary

This early-stage study aims to test the safety and immune response of an experimental Hepatitis C vaccine in healthy adults. The vaccine is designed to prevent Hepatitis C infection, which currently has no available vaccine and affects millions worldwide. Researchers will monitor participants for side effects and measure how well their bodies produce protective antibodies after vaccination.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATITIS C are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ottawa Hospital - General Campus

    Ottawa, Ontario, K1H 8L6, Canada

    Contact

  • Toronto General Hospital - Toronto Centre for Liver Disease

    Toronto, Ontario, M5G 2C4, Canada

    Contact

  • University of Alberta Hospital

    Edmonton, Alberta, T6G 2B7, Canada

    Contact

Conditions

Explore the condition pages connected to this study.